ATE235914T1 - Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen - Google Patents

Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen

Info

Publication number
ATE235914T1
ATE235914T1 AT96923511T AT96923511T ATE235914T1 AT E235914 T1 ATE235914 T1 AT E235914T1 AT 96923511 T AT96923511 T AT 96923511T AT 96923511 T AT96923511 T AT 96923511T AT E235914 T1 ATE235914 T1 AT E235914T1
Authority
AT
Austria
Prior art keywords
progression
inhibiting
neuropathic pain
achieveing
analgesia
Prior art date
Application number
AT96923511T
Other languages
English (en)
Inventor
Gary Arthur Amstutz
Stephen Scott Bowersox
Kishorchandra Gohil
Peter Isadore Adriaenssens
Ramasharma Kristipati
Theresa Gadbois
Mark Raymond Pettus
Robert R Luther
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/496,847 external-priority patent/US5795864A/en
Priority claimed from US08/613,400 external-priority patent/US6054429A/en
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of ATE235914T1 publication Critical patent/ATE235914T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of El Displays (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
AT96923511T 1995-06-27 1996-06-26 Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen ATE235914T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/496,847 US5795864A (en) 1995-06-27 1995-06-27 Stable omega conopetide formulations
US08/613,400 US6054429A (en) 1996-03-08 1996-03-08 Epidural method of producing analgesia
PCT/US1996/011041 WO1997001351A1 (en) 1995-06-27 1996-06-26 Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders

Publications (1)

Publication Number Publication Date
ATE235914T1 true ATE235914T1 (de) 2003-04-15

Family

ID=27052304

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96923511T ATE235914T1 (de) 1995-06-27 1996-06-26 Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen
AT03007342T ATE359086T1 (de) 1995-06-27 1996-06-26 Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03007342T ATE359086T1 (de) 1995-06-27 1996-06-26 Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen

Country Status (14)

Country Link
EP (2) EP1336409B1 (de)
JP (1) JP2838073B2 (de)
AT (2) ATE235914T1 (de)
AU (1) AU695166B2 (de)
CA (1) CA2224795C (de)
DE (3) DE69637021T2 (de)
DK (2) DK1336409T3 (de)
ES (2) ES2194998T3 (de)
FR (1) FR05C0027I2 (de)
HK (1) HK1058146A1 (de)
LU (1) LU91181I2 (de)
NL (1) NL300201I2 (de)
PT (2) PT1336409E (de)
WO (1) WO1997001351A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5931809A (en) * 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
CA2319038A1 (en) * 1998-02-20 1999-08-26 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
WO2004050688A1 (en) 2002-12-02 2004-06-17 Xenome Ltd NOVEL χ-CONOTOXIN PEPTIDES (-II)
ATE547424T1 (de) 2002-12-02 2012-03-15 Xenome Ltd Chi-conotoxinpeptide mit einer n-terminalen pyroglutaminsäure
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1594517B1 (de) 2003-01-28 2007-06-20 Microbia, Inc. Zusammensetzungen zur behandlung von gastrointestinalen störungen
WO2005032556A1 (en) 2003-10-02 2005-04-14 Elan Pharmaceuticals, Inc. Method for reducing pain
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
EP2077854B1 (de) * 2006-11-04 2013-01-23 Anygen Co., Ltd. Omega-conotoxine
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009135258A1 (en) * 2008-05-06 2009-11-12 Cnsbio Pty Ltd Methods and compositions for the management of pain using omega-conotoxins
EP3239170B1 (de) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
EP3241839B1 (de) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
CA2745694C (en) 2008-12-03 2018-03-27 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
KR101766619B1 (ko) 2008-12-31 2017-08-08 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR102138390B1 (ko) 2012-08-21 2020-07-27 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료에서 ｎｈｅ-매개된 역수송 저해를 위한 화합물 및 방법
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2983667B1 (de) 2013-04-12 2019-03-20 Ardelyx, Inc. Nhe3-bindende verbindungen und verfahren zur phosphattransporthemmung
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
WO2018129552A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
AU2018206479B2 (en) 2017-01-09 2022-07-14 Ardelyx, Inc. Inhibitors of NHE-mediated antiport

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
AU3074592A (en) * 1991-11-12 1993-06-15 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
EP0625162B1 (de) * 1991-12-30 1998-05-13 Neurex Corporation Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie
JPH06247879A (ja) * 1993-02-17 1994-09-06 Bristol Myers Squibb Co デオキシチミジンヌクレオシドを含有する注射用製剤の安定化方法およびその方法によって得られる安定化注射用製剤

Also Published As

Publication number Publication date
JPH09104634A (ja) 1997-04-22
DE69637021D1 (de) 2007-05-24
HK1058146A1 (en) 2004-05-07
AU6400296A (en) 1997-01-30
ES2194998T3 (es) 2003-12-01
DE69627153D1 (de) 2003-05-08
CA2224795A1 (en) 1997-01-16
DK0835126T3 (da) 2003-07-14
EP0835126B1 (de) 2003-04-02
ATE359086T1 (de) 2007-05-15
FR05C0027I1 (de) 2005-08-12
NL300201I1 (nl) 2005-09-01
FR05C0027I2 (de) 2006-12-29
WO1997001351A1 (en) 1997-01-16
DE122005000043I2 (de) 2006-08-03
PT1336409E (pt) 2007-06-29
DE69637021T2 (de) 2008-01-10
DE122005000043I1 (de) 2006-06-29
NL300201I2 (nl) 2006-02-01
PT835126E (pt) 2003-07-31
LU91181I2 (fr) 2005-09-06
EP1336409B1 (de) 2007-04-11
EP1336409A1 (de) 2003-08-20
AU695166B2 (en) 1998-08-06
ES2283671T3 (es) 2007-11-01
CA2224795C (en) 2001-04-03
DE69627153T2 (de) 2003-12-04
EP0835126A1 (de) 1998-04-15
JP2838073B2 (ja) 1998-12-16
DK1336409T3 (da) 2007-08-13

Similar Documents

Publication Publication Date Title
ATE359086T1 (de) Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen
PL323825A1 (en) Peptidyloheterocycli compounds useful in treating diorders associated with thrombosin
ES2052871T3 (es) Preparacion de bis (3,5-di-t-butil-4-hidroxifeniltio)metano.
ZA975323B (en) Use of strontium salts for the production of pharmaceutical compositions intended for the treatment of arthrosis.
MY131458A (en) Pyrolopyrimidine compounds
DE69117117T2 (de) Reinigungszusammensetzung zur Vorbeugung und Milderung von Hautreizungen
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
FI950909A (fi) Rasvahappojohdannaisia
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE9305147U1 (de) Trainingsgerät zur Behandlung von an Wahrnehmungsstörungen leidenden Patienten
DE59408857D1 (de) Vorrichtung zur kontinuierlichen Herstellung von Polyacetalen und ihre Verwendung
DE69402105D1 (de) Vorrichtung zur Herstellung von Elektreten
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
FR2710539B1 (fr) Ensemble d'aiguille chirurgicale.
ZA961897B (en) 6,7-substituted-2-aminotetralines and use thereof
DE9313771U1 (de) Vorrichtung zur Herstellung von Effektbeschichtungen
DE9320358U1 (de) Vorrichtung zur Herstellung von Tampons
DE9403254U1 (de) Vorrichtung zur Herstellung von Profilen und Formteilen
DE9314960U1 (de) Vorrichtung zur Herstellung von Fullerenen
NO984964L (no) Anvendelse av fosfonsyreestere for behandling av funksjonelle forstyrrelser i hjernen og ved depresjon
ATA217894A (de) Vorrichtung zur herstellung von brezeln
DE69407091T2 (de) Vorrichtung zur Herstellung von Ziegelsteinen
DE9314589U1 (de) Vorrichtung zur Druckbehandlung von Bahnen